Xxxxxxxxx, M Sample Clauses

Xxxxxxxxx, M. Do you really need a blockchain? xxxxx://xxxxxxx.xxx/ xxxxxxxxxxxxx/status/787760892783894528

Xxxxxxxxx, M. S., Xxx, P. C., Xxxxxxxx, X. X., Xxxxxx, C. N. & Xxxxxxxxx-Xxxx, B. Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials. Infect. Dis. Ther. 8, 445–452 (2019). 87. Xxxx, X. X., Xxxxxxx, X., Xxxxxx, X., Xxxxxxx, X. X., Xxxx, X. & Xxxxxxxx, S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. 49, 195–201 (2005). 88. Xxxx, X. X., Xxxxxxxx, X. X., Xxxx, X. X. & Xxxxxxxx, M. R. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J. Antimicrob. Chemother. 62, 780–783 (2008). 89. Xxxxxxx, X. X., Xxxx, X. X. & Xxxxxxxx, X. X. Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment. Eur. J. Clin. Pharmacol. 71, 707–714 (2015). 90. Xxxxxxxx, X. X. The ATTAIN trials: Efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. Future Microbiol. 9, 281–289 (2014). 91. Xxxxxxxxx, X. X., Xxxxx, X., Xxxxxxxx, X., Xxxxx, X., Xxxxxxxx, X., Xxxxxxxxx, X., Xxxxxxx, P., Xxxxxx, M., Xxxxxx, V. & Xxxxxxx, G. A40926, a new glycopeptide antibiotic with anti-Neisseria activity. Antimicrob. Agents Chemother. 31, 1961–1966 (1987). 92. Xxxxxxxxx, X. & Xxxxxxxxx, X. X. Origin, structure, and activity in vitro and in vivo of dalbavancin.

Xxxxxxxxx, M. H. et al. NT-3 gene delivery elicits growth of chronically injured corticospinal axons and modestly improves functional deficits after chronic scar resection. Exp Neurol 181, 47-56 (2003).

Xxxxxxxxx, M. Xxxxxxxxx, A.; Xxxxxxxxx, X.; Xxxxxxx, X.X.; Xxxxxxxxxxxxxx, D.; Xxxxxxxxxx, M.; Xxxxx, X.X.; Xxxxxx, T.; Xxx, X.; xx Xxxxxx, P.I., et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. The New England journal of medicine 2011, 364, 1134-1143, doi:10.1056/NEJMoa1013297.

Xxxxxxxxx, M. A.; Xxxxxxxx, X.X.; Xxxxxxxx, X.X. Viral Vectors for Gene Therapy: Translational and Clinical Outlook. Annu. Rev. Biomed. Eng. 2015, 17, 63–89, doi:10.1146/annurev-bioeng-071813-104938.

Xxxxxxxxx, M. H. et al. Fibroblasts genetically modified to produce nerve growth factor induce robust neuritic ingrowth after grafting to the spinal cord. Exp Neurol 126, 1-14 (1994).

Xxxxxxxxx, M. A., Xxxxxxxxx, R. (1994).

Xxxxxxxxx, M. D., Lagz Corporation, Spine & Pain Treatment Medical Center of Santa Xxxxxxx, Inc., and LAGS Spine & Sportscare Medical Centers, Inc., Case No. 2:18-cv-2928 KJM KJN, pursuant to the qui tam provisions of the False Claims Act, 31 U.S.C. § 3730(b) (“FCA”) and the California False Claims Act, Cal. Gov’t Code § 12652(c) (“CFCA”) (the “Civil Action”). Relator alleges, inter alia, that Xx. Xxxxxxxxx, Lags Spine & Sportscare Medical Centers, Inc., LAGZ Corporation, and Spine and Pain Medical Treatment Center of Santa Xxxxxxx, Inc., submitted false claims to Medicare and Medi-Cal for services and procedures that were not reasonable or necessary in violation of the FCA and CFCA.

Xxxxxxxxx, M. T. Xxxxxx, X. Xxxxxxxxxx, X. X. XxXxxxx, and X.-X. Quisquater. Authentication protocols for ad hoc networks: taxonomy and research issues. In Q2SWinet ’05: Proceedings of the 1st ACM international workshop on Quality of service & security in wireless and mobile networks, pages 00–000, Xxx Xxxx, XX, XXX, 0000. ACM Press.

Xxxxxxxxx, M. Getting SSI Disability Benefits for a Child With a Congenital Heart Defect. (xxxx://xxx.xxxxxxxxxxxxxxxxx.xxx/resources/disability/child- disability/getting-ssi-disability-benefi). (Accessed January 30, 2016)